grant
Preventing invasive prostate cancer
Organization UNIVERSITY OF NEBRASKA MEDICAL CENTERLocation OMAHA, UNITED STATESPosted 19 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY20253-D3-Dimensional3DAchievementAchievement AttainmentActin-Binding ProteinAddressAdhesionsAffectAffinityAnimalsAntioncogene Protein p53AssayAutopsyBindingBinding SitesBioassayBiochemicalBioinformaticsBiologicalBiological AssayBiological MarkersBiophysicsBloodBlood Reticuloendothelial SystemBody TissuesCDC37CDC37 Cell Division Cycle 37 Homolog (S. cerevisiae) GeneCDC37 Homolog GeneCDC37 geneCalorimetryCancersCanine SpeciesCanis familiarisCarcinoma in SituCause of DeathCell BodyCell Communication and SignalingCell FunctionCell LocomotionCell MigrationCell MovementCell PhysiologyCell ProcessCell SignalingCellsCellular FunctionCellular MigrationCellular MotilityCellular OncogeneCellular PhysiologyCellular ProcessCellular Tumor Antigen P53ChromansClinicalCombining SiteCommon Rat StrainsComplexCoupledDataDevelopmentDihydrobenzopyransDiseaseDisorderDogsDogs MammalsDrugsEngineeringHSP-90HSP90Heat-Shock Proteins 90Hsp90 Chaperone Protein Kinase-Targeting Subunit GeneHsp90 Co-Chaperone Cdc37 GeneHumanImageIn SituIn Situ LesionIn VitroIndividualInterceptInterventionIntracellular Communication and SignalingIntraepithelial CarcinomaInvadedInvestigatorsJournalsKnowledgeL-PlastinL-Plastin GeneLC64PLCP1LCP1 geneLymphocyte Cytosol Polypeptide 64-KDLymphocyte Cytosolic Protein 1MagazineMalignant CellMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMediatingMedicationMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic Prostate CancerMetastatic TumorMiceMice MammalsModelingModern ManMolecularMolecular InteractionMotilityMovementMurineMusNatureNeoplasm MetastasisOncoprotein p53OrganoidsP50CDC37 GeneP53PLS2Pathway interactionsPersonsPharmaceutical PreparationsPhenotypePhosphoprotein P53Phosphoprotein pp53PhosphorylationPlastin 2Preinvasive CarcinomaPreventionProstateProstate CAProstate CancerProstate Carcinoma MetastaticProstate GlandProstate malignancyProstatic GlandProstatic ParenchymaProstatic TissueProtacProtein PhosphorylationProtein TP53ProteinsProteolysis targeting chimericProteomeProteomicsProto-OncogenesRatRats MammalsRattusReactive SiteRegulationRegulatory PathwayResearch PersonnelResearchersRiskRoleSafetySecondary NeoplasmSecondary TumorSignal PathwaySignal TransductionSignal Transduction SystemsSignalingSpecificitySubcellular ProcessSystemTP53TP53 geneTRP53TestingTherapeuticTissuesTitrationsToxicokineticsTransgenic ModelTreatment EfficacyTumor Protein p53Tumor Protein p53 Genebio-markersbiologicbiologic markerbiological signal transductionbiomarkerbiophysical foundationbiophysical principlesbiophysical sciencesbody movementbonec-ONCcancer cellcancer invasivenesscancer metastasiscancer preventioncancer typecaninecell motilitycell typechemoproteomicsclinical relevanceclinically relevantcomputer based predictiondetermine efficacydevelopmentaldomestic dogdrug/agentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyexamine efficacyhsp90 Familyhuman diseasehuman modelimagingin silicoin situ cancerinhibitorinnovateinnovationinnovativeintervention efficacykinase inhibitorluminescencemalignancymass spectrometermembermodel of humanmonomernecropsyneoplasm/cancernovelp53 Antigenp53 Genesp53 Tumor Suppressorpathwaypharmacologicpostmortempredictive modelingpreventpreventingprogramsprostate cancer cellprostate tumor cellprotein p53proteolysis targeting chimaeraproteolysis targeting chimeraprotooncogenesocial roletherapeutic efficacytherapy efficacythree dimensionaltooltransgenic traittumor cell metastasis
Description preview
Abstract: Cell motility is required for in situ cancer to form invasive primary prostate cancer (PCa). Inhibiting
motility would intercept formation of invasive cancer. Until now it has not been possible to selectively inhibit
motility. We have discovered a precision acting first-in-class agent, KBU2046. It selectively inhibits motility, has
a…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click